Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.55 |
| ▸ | TP53 | P04637 | 6/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4767939 | 0.99 | MEN1 (0.57) | MEN1KMT2ASMN1; SMN2TP53MAPT | |
| SCHEMBL4774462 | 0.86 | RAB9A (0.59) | MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL4765359 | 0.86 | NPC1 (0.44) | MEN1KMT2ASMN1; SMN2TP53MAPT | |
| Hydrochloric Acid SCHEMBL4772031 | 0.85 | NPC1 (0.43) | MEN1KMT2ASMN1; SMN2TP53MAPT | |
| SCHEMBL4765960 | 0.84 | NR1H4 (0.52) | SMN1; SMN2MAPTALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL4770084 | 0.83 | NR1H4 (0.51) | SMN1; SMN2MAPTALDH1A1POLB | |
| SCHEMBL4765178 | 0.83 | ALDH1A1 (0.58) | KMT2AMAPTGAAALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL4765416 | 0.82 | ALDH1A1 (0.57) | KMT2AMAPTGAAALDH1A1POLB | |
| SCHEMBL4767352 | 0.81 | ALDH1A1 (0.54) | MEN1KMT2ASMN1; SMN2TP53MAPT | |
| SCHEMBL4765564 | 0.80 | HRH3 (0.46) | MEN1KMT2ASMN1; SMN2TP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | MEN1 2213/4885KMT2A 99/4885SMN1; SMN2 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.